论文部分内容阅读
目的:探讨亚胺培南联合常用抗菌药物对blan KPC-2型碳青霉烯类耐药肺炎克雷伯菌（CRKP）的体外抗菌作用。n 方法:选取乐清市人民医院2018年1月至2019年1月分离的6株非重复的经聚合酶链反应和DNA序列确认的blan KPC-2型CRKP菌株，测量其对常用9种抗菌药物的敏感率，采取棋盘稀释法进行亚胺培南联合8种抗菌药物的药物敏感性试验，计算部分抑菌浓度指数（FIC）并评价联合应用效果；通过绘制体外时间-杀菌曲线评估联合用药的杀菌作用。n 结果:6株blan KPC-2型CRKP菌株对亚胺培南、美罗培南、头孢他啶、环丙沙星、利福平、头孢噻肟等抗菌药物耐药率为100.00％（6/6），对米诺环素、克拉维酸耐药率为66.67％（4/6），对替加环素耐药率为33.33％（2/6）；亚胺培南联合替加环素抗菌作用较好，对4株起协同作用、2株起相加作用；以菌株KPN2进行亚胺培南联合替加环素治疗的时间-杀菌曲线显示：菌株KPN2在亚胺培南1/2最低抑菌浓度（MIC）与替加环素1/4 MIC在（t+2）时杀菌率>95％，此作用可维持（t+10）h至（t+12）h，亚胺培南联合替加环素对002杀菌率逐步降低，002生长曲线逐渐上升。n 结论:体外药物敏感性试验显示，亚胺培南联合替加环素对blan KPC-2型CRKP具有较好协同杀菌作用，可供临床治疗blan KPC-2型CRKP感染患者时参考。n “,”Objective:To investigate the n in vitro antibacterial effects of imipenem combined with common antibiotics on blan KPC-2 type carbapenem resistant klebsiella pneumoniae (CRKP) targeting blan KPC-2 gene.n Methods:Six strains of unrepeated blan KPC-2 type confirmed by polymerase chain reaction and DNA sequence were isolated in Yueqing People's Hospital, China between January 2018 and January 2019 were included in this study. The susceptibility rate of imipenem against nine conventionally used antibiotics was determined. The sensitivity test of imipenem combined with eight antibiotics was performed with the checkerboard method. Fractional inhibitory concentration was calculated to assess the efficacy of imipenem combined with common antibiotics. The n in vitro treatment time-antibacterial effect curve was drawn to evaluate the antibacterial effects.n Results:The resistance rate of six strains of blan KPC-2 type was 100.00% (6/6) for imipenem, meropenem, ceftazidime, ciprofloxacin, rifampicin and cefotaxime, and it was 66.67% (4/6) for minocycline and clavulanic acid and 33.33% (2/6) for tigecycline. Imipenem combined with tigecycline had a better antibacterial effect and exhibited a synergistic effect on four strains of blan KPC-2 type CRKP and an additive effect on two strains of Blan KPC-2 type CRKP. The curve of time for n in vitro treatment of KPN2 with imipenem combined with tigecycline against bactericidal effect revealed that the antibacterial rate of imipenem at the 1/2 minimum inhibitory concentration combined with tigecycline at the 1/4 minimum inhibitory concentration was > 95% at (t+2) and the antibacterial effect could maintain (t+10) hours to (t+12) hours. The antibacterial rate of imipenem combined with tigecycline against strain 002 was gradually decreased with time, and the growth curve of strain 002 rised gradually.n Conclusion:In vitro drug sensitivity test revealed that imipenem combined with tigecycline exhibits a good synergistic effect on blan KPC-2 type CRKP. Findings from this study provide a reference for clinical treatment of blan KPC-2 type CRKP.n